Share This Article:

The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study

Abstract Full-Text HTML XML Download Download as PDF (Size:241KB) PP. 297-302
DOI: 10.4236/jct.2016.74031    1,201 Downloads   1,559 Views  

ABSTRACT

Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin®) 85 mg/m2 D1, 5-Fluorouracil 400 mg/m2 IV push D1-2, 5-Fluorouracil 600 mg/m2 IV drip in 22 hours D1-2 and Folinic acid 200 mg/m2 IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible.

Received 10 March 2016; accepted 25 April 2016; published 28 April 2016

1. Introduction

Cervical cancer is one of the most common gynecological cancers in Thailand. From our hospital status, the incidence rate of cervical cancer was 22.7 in the year of 2005 [1] . For locally advanced cervical cancer, concurrent chemo-radiotherapy showed more benefits than radiotherapy alone [2] - [4] . For metastatic disease, chemotherapy is the treatment of choice. However, platinum-based regimen has not led to major improvements in clinical outcome and is associated with higher rate of severe toxicities [5] . A randomized study of cisplatin alone versus cisplatin/paclitaxel demonstrated improvements of response and disease-free survival rates in favors of combined regimen, but there was no difference in overall survival rate [6] . Other studies reported lower response rates of re-challenge treatment, and suggested that additional topotecan enhanced the response and survival rates [7] . The randomized trial of four-containing doublet combinations of various cisplatin-based doublets reported no difference of treatment results [8] .

Oxaliplatin (Oxaliplatin (L-OHP; trans-oxalate(2-)-O,O platinum)) is platinum-based chemotherapy which found in laboratory that needed less DNA adducts amount to develop toxicity than cisplatin. Oxaliplatin showed efficacy to many cancer cells. From the phase I study program of oxaliplatin, the recommended dose for use in single agent was 130 mg/m2 [9] . In phase II study, single oxaliplatin in squamous cell carcinoma of the cervix showed around 8% response rate [10] . However, the treatment of metastatic cancer at present is combinations regimen [11] . According to the profiles of oxaliplatin, the use in cervical cancer is interesting. This study planned to evaluate the FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer.

2. Materials and Methods

2.1. Patient Selection and Data Collection

This study was approved by Institutional Review Board with the study code of OXALI_L_05049 and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The inclusion criteria were as follows: age 18 - 70 years, at least clinically proven metastatic cervical carcinoma, clinical (by clinical examination and imaging) or pathological confirmation of metastasis setting to distant lymph nodes (paraaortic lymph node/ supraclavicular lymph node) or other visceral metastasis, no history of allergy. Previous concurrent chemoradiotherapy or systemic chemotherapy was allowed. Written informed consent was obtained from all participants prior to study commencement.

Common Terminology Criteria of Adverse Events (CTCAE) version 3.0 was used to measure adverse events during chemotherapy and during follow-up time [12] . Response rates were evaluated after 6th cycle, 12th cycle and every 3 months until progression with WHO criteria and RECIST criteria according to measured sites [13] [14] .

2.2. Treatment

All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin®) 85 mg/m2 on D1, 5-Flu- orouracil 400 mg/m2 IV push D1-2, 5-Fluorouracil 600 mg/m2 IV drip in 22 hours D1-2 and Folinic acid 200 mg/m2 IV push D1-2) with 2-weeks interval. The planned schedule was 12 cycles of chemotherapy and evaluation was performed after 6th and 12th cycle.

2.3. Statistical Analysis

The goal of this study was to study the efficacy and safety of FOLFOX4 regimen for the treatment of metastatic cervical cancer. The primary endpoints were the one-year progression free and overall survival rates. The secondary endpoint was toxicity profile. Descriptive and qualitative analyses were evaluated by the statistical package for social sciences (SPSS, version 17). Survival analysis data were calculated by Kaplan-Meier method and log-rank test [15] [16] .

3. Results

After the approval of the Institutional Review Board, 30 patients were enrolled into the study from January 2010-December 2012. Written informed consent was obtained from all participants prior to study commencement.

The characteristics of enrolled patients are shown in Table 1. The mean age was 51 years old. Seventy percent (21/30) had distant lymph node metastasis. Forty-three percent could receive less than 6 cycles and progression of disease was the main reason for treatment discontinuation. One patient died during the first cycle due to non-cancer cause (cardiac problem), so twenty-nine patients could be evaluated in terms of efficacy. One of 29 patients received the FOLFOX4 regimen as second-line treatment. The mean progression-free survival was 7.6 months (interquartile range (IQR): 3 - 12.5 months).

Thirty-one percent of patients (9/29) yielded objective response (CR and PR) and twenty-eight percent of them had stable of disease. Fifty-nine percent of patients could receive at least 6 cycles of chemotherapy. Treatment delayed and/or dose reduction was reported at least one episode in 22 patients. The data are shown in Table 2.

Safety could be evaluated in 30 patients. Adverse events during treatment, any grade, during chemotherapy were leucopenia (56.7%), fatigue (50%) and anemia (46.7%). The most common grade 3 adverse events reported in this study were anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Grade 3 renal impairment and peripheral neuropathy were developed in 3 patients (10%) and 4 patients (13.3%), respectively. All safety profiles data were showed in Table 3.

4. Discussion

Oxaliplatin-based regimen mostly used for treatment of metastatic colorectal and pancreatic cancers with promising results [17] - [20] . In our department, many regimens of chemotherapy were used to treat metastatic cervical cancer. Lorvidhaya et al. reported the efficacy of combination chemotherapy using Cisplatin and Epirubicin in carcinoma of the cervix. Fifty-six patients with local recurrent and/or metastatic carcinoma of the cervix have

Table 1. Patient characteristic.

Table 2. Treatment results in patients who received FOLFOX4 regimen for metastatic cervical cancer.

aExcluded one patient who died during the first cycle. Note: OS = overall survival, PFS = Progression-free survival, IQR = Interquartile range.

Table 3. Safety profile of patients.

been treated using Cisplatin 60 mg/m2 and Epirubicin 90 - 100 mg/m2 every three weeks. The overall response rate was 67.9% (CR 14.3%, PR 53.6%). Four out of fourteen patients in stage IVB had long-term survival ranging from 14 to 85 months. Grade 4 leucopenia occurred in 20% [21] .

Chitapanarux et al. reported the efficacy and tolerability of irinotecan plus cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Thirty “chemotherapy-naïve” patients with metastatic or recurrent disease and at least one measurable tumor site received irinotecan (60 mg/m2 IV infusion over 90 min) on D1, D8, and D15, followed by cisplatin (60 mg/m2 IV infusion over 90 minutes) on D1, every 28 days for a maximum of six cycles. The median (range) age was 45 years (34 - 65). Nineteen patients had metastatic disease, 6 presented with locally recurrent disease, and 5 presented with locally recurrent plus metastatic disease. The overall response rate was 66.7%. Stable disease and progression disease were observed in 2 patients (6.7%) and 8 patients (26.7%), respectively. Median time to relapse was 13.4 months, with a median survival time of 16.9 months. One-year disease-free survival and overall survival were 26.7% and 65.1%, respectively. Dose-limiting toxicity was observed in 4 patients (13.3%) with grade 3 renal toxicity. Nine patients (30%) developed grade 3 neutropenia, and only grade 1-2 acute and late diarrhea were observed in 20% and 40%, respectively [22] .

Kamnerdsupaphon et al. reported the therapeutic efficacy of cisplatin in combination with vinorelbine in the treatment of patients with metastatic cervical cancer. Seventeen patients were enrolled in the present study. The median age was 46 years (38 - 65). There were 6 patients who were diagnosed as stage IVB cervical cancer without previous treatment. The patients were planned to receive cisplatin 80 mg/m2 on D1 and vinorelbine at 30 mg/m2 on D1 and D8 every 3 weeks. Fifteen patients were available for evaluation: 2 (13.3%) achieved a complete response, 8 (53.4%) partial responses, 3 (20%) stable diseases and 2 (13.3%) progression of the disease. Myelosuppression was the major toxicity Grade 3/4 toxicities include 66.7% hemoglobin and 26.7% neutropenia. No other significant side effects were found [23] .

The use of oxaliplatin-based regimen was further evaluated. Kuo et al. reported the efficacy and toxicity of paclitaxel and oxaliplatin in patients with recurrent or metastatic cervical cancer. Treatment consisted of paclitaxel 175 mg/m2 IV and oxaliplatin 130 mg/m2 IV every 21 days. Of the 35 patients enrolled, 32 were evaluable. The median (range) age was 56 (27 - 78) years; 30 had prior radiation (23 concomitant with cisplatin). Patients completed a mean of 4.2 cycles (1 - 11). There were 2 complete and 5 partial responses for a total response rate of 7/32 (22%; 95% CI: 9.3 - 40.0). Eight patients had stable disease for an overall clinical benefit rate of 15/32 (47%; 95% CI: 29.1 - 65.3). The mean time to best response was 13.5 weeks (95% CI: 10.6 - 16.4). The mean progression-free survival was 21 weeks (95% CI: 14.7 - 27.2) and mean overall survival was 52 weeks (95% CI: 39.4 - 64.8). A total of 135 cycles were administered. There were 28 (20.1%) grade 3/4 hematologic toxicities and 46 (34.1%) grade 3/4 non-hematologic toxicities, which were predominantly sensory neuropathy. There were 13 treatment delays, 4 dose reductions, and no treatment-related deaths. The author concluded that the combination of paclitaxel and oxaliplatin is an effective regimen in patients with recurrent or persistent cervical cancer including a majority previously exposed to cisplatin [24] .

For our experiences of using FOLFOX4 in recurrent or metastatic cervical cancer, 31% of our patients received objective response after treatment with the mean time to progression of 7.6 months. Fifty-nine percents received more than six cycles. With the mean follow-up time of 13 months, the 1-year progression-free survival and overall survival rates were 20.7% and 65.5%, respectively. Common toxicities, any grade, during chemotherapy were leucopenia (56.7%), fatigue (50%) and anemia (46.7%). When we compared these results to our previous studies, [21] - [23] the treatment results were comparable.

5. Conclusion

In conclusion, FOLFOX4 regimen can be used in metastatic cervical cancer with manageable safety profile.

Acknowledgements

The author wishes to thank sanofi-aventis (Thailand) Ltd. for providing investigational medicinal product, Eloxatin®, to the patients in this study.

Conflict of Interests

No conflict of interests is reported for the author.

NOTES

*Corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Tharavichitkul, E. , Tharavichitkul, E. , Chakrabandhu, S. , Klunklin, P. , Onchan, W. , Supawongwattana, B. , Pukanhaphan, N. and Chitapanarux, I. (2016) The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study. Journal of Cancer Therapy, 7, 297-302. doi: 10.4236/jct.2016.74031.

References

[1] Kamnerdsupaphon, P., Srisukho, S., Sumitsawan, Y., et al. (2008) Cancers in Northern Thailand. Biomedical Imaging and Intervention Journal, 4, e46.
http://dx.doi.org/10.2349/biij.4.3.e46
[2] Rose, P.G., Bundy, B.N., Watkins, E.B., et al. (1999) Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer. New England Journal of Medicine, 340, 1144-1153.
http://dx.doi.org/10.1056/NEJM199904153401502
[3] Whitney, C.W., Sause, W., Bundy, B., et al. (1999) Randomized Comparison of Fluorouracil plus Cisplatin versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix with Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. Journal of Clinical Oncology, 17, 1339-1348.
[4] Morris, M., Eifel, P.J., Lu, J., et al. (1996) Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer. New England Journal of Medicine, 340, 1137-1143.
http://dx.doi.org/10.1056/NEJM199904153401501
[5] Omura, G.A. (1996) Chemotherapy for Stage IVB or Recurrent Cancer of the Uterine Cervix. J Natl Cancer Inst Monogr, 21, 123-126.
[6] Moore, D.H., Blessing, J.A., McQuellon, R.P., et al. (2004) Phase III Study of Cisplatin with or without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 22, 3113-3119.
http://dx.doi.org/10.1200/JCO.2004.04.170
[7] Long 3rd, H.J., Bundy, B.N., Grendys Jr., E.C., et al. (2005) Randomized Phase III Trial of Cisplatin with or without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 23, 4626-4633.
http://dx.doi.org/10.1200/JCO.2005.10.021
[8] Monk, B.J., Sill, M.W., McMeekin, D.S., et al. (2009) Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 27, 4649-4655.
http://dx.doi.org/10.1200/JCO.2009.21.8909
[9] Taguchi, T., Tsukagoshi, S., Furue, H., et al. (1998) Phase I Clinical Study of Oxaliplatin. Gan To Kagaku Ryoho, 25, 1899-1907.
[10] Fracasso, P.M., Blessing, J.A., Wolf, J., et al. (2003) Phase II Evaluation of Oxaliplatin in Previously Treated Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Gynecologic Oncology, 90, 177-180.
http://dx.doi.org/10.1016/S0090-8258(03)00253-1
[11] Raymond, E., Chaney, S.G., Taamma, A. and Cvitkovic, E. (1998) Oxaliplatin: A Review of Preclinical and Clinical Studies. Annals of Oncology, 9, 1053-1071.
http://dx.doi.org/10.1023/A:1008213732429
[12] Trotti, A., Colevas, A.D., Setser, A., et al. (2003) CTCAE v3.0: Development of a Comprehensive Grading System for the Adverse Effects of Cancer Treatment. Seminars in Radiation Oncology, 13, 176-181.
http://dx.doi.org/10.1016/S1053-4296(03)00031-6
[13] Miller, A.B., Hoogstraten, B., Staquet, M. and Winkler, A. (1981) Reporting Results of Cancer Treatment. Cancer, 47, 207-214.
http://dx.doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
[14] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute, 92, 205-216.
http://dx.doi.org/10.1093/jnci/92.3.205
[15] Kaplan, E.L. and Meier, P. (1958) Non-Parametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457-481.
http://dx.doi.org/10.1080/01621459.1958.10501452
[16] Mantel, N. (1966) Evaluation of Survival Data and Two New Rank Order Statistics Arising in Its Consideration. Cancer Chemotherapy Reports. Part 1, 50, 163-170.
[17] De Gramont, A., Figer, A., Seymour, M., et al. (2000) Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology, 18, 2938-2947.
[18] Cassidy, J., Tabernero, J., Twelves, C., et al. (2004) XELOX (Capecitabine plus Oxaliplatin): Active First-Line Therapy for Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 22, 2084-2091.
http://dx.doi.org/10.1200/JCO.2004.11.069
[19] Goldberg, R.M., Rothenberg, M.L., van Cutsem, E., et al. (2007) The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. The Oncologist, 12, 38-50.
http://dx.doi.org/10.1634/theoncologist.12-1-38
[20] Alberts, S.R., Townley, P.M., Goldberg, R.M., et al. (2003) Gemcitabine and Oxaliplatin for Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Study. Annals of Oncology, 14, 580-585.
http://dx.doi.org/10.1093/annonc/mdg170
[21] Lorvidhaya, V. (1995) Epirubicin and Cisplatin in Recurrent, Metastatic or Advanced Carcinoma of the Cervix. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 22, 252-255.
[22] Chitapanarux, I., Tonusin, A., Sukthomya, V., Charuchinda, C., Pukanhapan, N. and Lorvidhaya, V. (2003) Phase II Clinical Study of Irinotecan and Cisplatin as First-Line Chemotherapy in Metastatic or Recurrent Cervical Cancer. Gynecologic Oncology, 89, 402-407.
http://dx.doi.org/10.1016/S0090-8258(03)00174-4
[23] Kamnerdsupaphon, P., Chitapanarux, I., Tharavichitkul, E., Sukthomya, V. and Lorvidhaya, V. (2009) The Study of Cisplatin and Vinorelbine in Metastatic Uterine Cervical Cancer. Journal of the Medical Association of Thailand, 92, 836-840.
[24] Kuo, D.Y., Blank, S.V., Christos, P.J., et al. (2010) Paclitaxel plus Oxaliplatin for Recurrent or Metastatic Cervical Cancer: A New York Cancer Consortium Study. Gynecologic Oncology, 116, 442-446.
http://dx.doi.org/10.1016/j.ygyno.2009.10.082

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.